Pharmacotherapy for the Different Phenotypes of Airways Disease

Phase 4

Completed

• Conditions: Asthma; Chronic obstructive pulmonary disease (COPD); Airways disease; Respiratory - Asthma; Respiratory - Chronic obstructive pulmonary disease

• Registration Number: ACTRN12610000666022
• Lead Sponsor: Medical Reseach Institute of New Zealand

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-08-16
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 16500

Inclusion Criteria

selected at random from the electoral register
wheeze and shortness of breath in the last 12 months

Exclusion Criteria

Unable or unwilling to withhold medication prior to study visits. Hypersensitivity to study drug.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
difference in forced expiratory volume in one second (FEV1) response to ipratropium between groups. This will be measured by spirometry.[At baseline and 30 minutes following administration of ipratropium.];difference in FEV1 response to salbutamol between groups. This will be measured by spirometry.[At baseline and 30 minutes following administration of salbutamol.]

Secondary Outcome Measures

Name	Time	Method
Change in symptoms and control of airways disease in response to inhaled corticosteroid as measured by Asthma Control Questionnaire.[At baseline and 12 weeks following commencement of treatent.]